Minoxidil

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

The review highlights that while FDA-approved treatments are limited, natural supplements like saw palmetto and pumpkin seed oil show promise in inhibiting 5-alpha-reductase and promoting hair density.

The review discusses the potential of topical dutasteride and nanocarrier delivery systems to provide an effective alternative to oral treatments while minimizing systemic absorption.

The review summarizes that finasteride and minoxidil are the primary approved treatments, while noting ongoing development of drugs targeting inflammation, fibrosis, and energy metabolism.

The study investigates the comparative efficacy of topical minoxidil, oral biotin, and their combination on hair growth in men, but specific numeric results are not provided in the abstract.

A combined rosemary and neem extract (2:1) demonstrated superior antifungal activity against dandruff-causing agents compared to ketoconazole and outperformed minoxidil in hair growth trials.

Several natural ingredients including saw palmetto, pumpkin seed oil, melatonin, caffeine, and rosemary oil showed effectiveness in treating AGA compared to baseline or minoxidil.

The review summarizes the potential of various herbal compounds, specifically highlighting rosemary oil as a promising natural alternative for managing androgenetic alopecia.

Combination therapy of topical minoxidil and microneedling significantly increases total hair count compared to minoxidil alone, though it did not show a statistically significant increase in hair diameter.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

Low-dose oral minoxidil has demonstrated a favorable efficacy and safety profile for both male and female androgenetic alopecia.

The paper outlines standard treatments for different alopecia types, noting minoxidil as first-line for androgenetic alopecia and various therapies for focal hair loss.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Chemotherapy-induced alopecia affects approximately 65% of patients; current FDA-cleared prevention is limited to scalp cooling, while regrowth options include minoxidil, PBMT, and PRP.

Standard treatments like topical minoxidil and oral finasteride are established, while newer modalities like PRP, LLLT, and oral minoxidil show encouraging results but lack standardized protocols.

The review provides an update on FDA-approved treatments (minoxidil and finasteride) as well as various non-FDA-approved, emerging, and alternative therapies for AGA.

Topical minoxidil remains the first-choice treatment with high evidence, though approximately 40% of patients do not respond to it.

The review discusses various promising topical, oral, and energy-based therapies, noting growing evidence for their efficacy in treating hair loss.

Natural products such as saw palmetto, caffeine, and rosemary oil may serve as alternatives or adjuncts to conventional minoxidil and finasteride treatments for male AGA.

The review outlines various current and emerging therapies for hair loss, including pharmacological agents, devices, and cellular therapies.

Microneedling serves as an effective adjunct therapy for androgenic alopecia when paired with minoxidil, growth factors, or PRP, and shows promise as a standalone therapy for alopecia areata.

Traditional treatments like corticosteroids and minoxidil have limited efficacy and high recurrence rates, while new strategies like JAK inhibitors and biologics are emerging.

Topical minoxidil is effective for AGA in both sexes, with 2% showing peak growth at one year. Oral minoxidil (5 mg/day) is significantly more effective than topical formulations in males after 6 months.

Topical finasteride (0.25% spray or 1% gel) demonstrates efficacy similar to 1 mg oral finasteride in increasing hair density and inhibiting plasma DHT.

Dutasteride 0.5 mg/d is ranked as the most effective treatment, followed by higher doses of finasteride and minoxidil.

Topical finasteride, ketoconazole, and C17P show promise for male pattern hair loss, with topical finasteride particularly effective when combined with minoxidil. C17P shows potential for acne vulgaris.

Microneedling monotherapy is more effective than 5% topical minoxidil alone, and combining microneedling with 5% minoxidil provides a significant additional increase in total hair count compared to microneedling monotherapy.

The review outlines various FDA-approved and non-FDA-approved therapies for AGA, emphasizing that treatment selection must balance efficacy, side effects, compliance, and cost.

Oral minoxidil at low doses is an effective alternative to topical formulations, particularly for patients with compliance issues.

Combined finasteride and topical minoxidil therapy yields better overall photographic assessment and more marked improvement compared with either monotherapy, while showing similar rates of moderate/mild improvement, hair density change, and adverse events.

Topical minoxidil and oral anti-androgens are the primary treatments aimed at halting progression and promoting cosmetically acceptable hair regrowth in female pattern hair loss.

Finasteride and minoxidil can halt disease progression but only yield partial hair regrowth; early initiation improves outcomes, and PRP may be considered for patients unresponsive to medical therapy.

Herbal drugs may reduce hair loss by inhibiting the 5-alpha-reductase enzyme with potentially fewer side effects than conventional pharmacological treatments.

The study investigated low-dose oral minoxidil for treating male pattern hair loss; specific efficacy results are not available from the abstract.

First-line therapies recommended include oral finasteride 1 mg daily, oral dutasteride 0.5 mg daily, topical 5% minoxidil twice daily for MPHL and topical 1% minoxidil twice daily for FPHL, along with low-level laser therapy and hair transplantation.

The review highlights several emerging therapies, including novel excipients for oral minoxidil, dutasteride, and finasteride; topical prostaglandin modulators; low-level laser therapy; Wnt pathway activators and stem cell treatments for androgenetic alopecia; JAK inhibitors for alopecia areata; antiandrogens and pioglitazone for frontal fibrosing alopecia; and robotic-assisted follicular unit extraction for hair transplantation.

Minoxidil, finasteride, and low-level laser therapy were significantly more effective than placebo for promoting hair growth in men with androgenetic alopecia, and minoxidil was effective in women.

Treatments such as topical minoxidil and 5‑alpha reductase inhibitors (finasteride, dutasteride) can slow hair loss progression and promote regrowth, but continuous use is required to maintain benefit.

5% topical minoxidil produced significantly greater hair regrowth than 2% minoxidil and placebo, with 45% more regrowth versus 2% at week 48, earlier onset of response, and improved psychosocial perceptions of hair loss.

Both ketoconazole shampoo and minoxidil produced similar improvements in hair density, follicle size, and proportion of anagen follicles in patients with androgenic alopecia.